Biopure Corporation Case Study Richard Addington PHD Table of Contents 1. Executive Summary 2. Situation Analysis a. Human Blood Demand b. Human Blood Pricing c. RBC limitations 3. Internal Environment d. Strengths and weaknesses of Oxyglobin e. Strengths and weaknesses of Hemopure 4. External/Competitive Environment f. Baxter g. Northfield h. Biopure 5. Animal Blood Market 6. Marketing Plan i. Positioning j. Pricing
Premium Blood Blood transfusion
www.hbr.org Even as companies are being told that the future lies in globalization‚ some are severely punished for their international moves. A simple test can help you decide what makes strategic sense for your organization. When You Shouldn’t Go Global by Marcus Alexander and Harry Korine Included with this full-text Harvard Business Review article: 1 Article Summary The Idea in Brief—the core idea The Idea in Practice—putting the idea to work 2 When You Shouldn’t Go Global 8 Further
Premium Globalization
How best to exploit the opportunity presented by Oxyglobin without jeopardizing the potential of Hemopure is a tough problem for Biopure’s executive. According to the financial analysis‚ it is suggested that Biopure begin to sell Oxyglobin at $150 per unit to emergency care practice at the Veterinary Blood Market and have its own distribution network. This will make a profit of $5 million at first year and $17 million thereafter. The steadfast income will consolidate Biopure’s financial structure
Premium Blood Marketing Economics
Decision Sheet – Biopure Corporation Marketing Objective – Whether to launch Oxyglobin now or delay it till the approval of Hemopure. If yes‚ then devise a marketing plan for Oxyglobin. Options – 1. Launch Oxyglobin in the market immediately. 2. Defer the launch of Oxyglobin now till Hemopure release. Recommendation – Biopure Corporation should immediately launch Oxyglobin priced at $200. Rationale – Applying SWOT Analysis to the situation: Strengths 1. FDA approval has already come
Premium Blood Blood transfusion Marketing
Biopure Corporation Written Case Study I. Current Situation Audit A. Issue Oxyglobin and Hemopure are two blood substitutes that Biopure Corporation was developing. Oxyglobin was recently approved by the FDA for veterinary use while Hemapure is estimated to be approved in two years for human use. If Oxyglobin is launched it will be the first blood substitute for the veterinary market a small and price sensitive market. There is a perceived risk by Ted Jacobs‚ the VP of Human Clinical Trials
Free Blood Blood transfusion
1. a) Potential market for Humans To accurately calculate the number of units that would be required per year in the human market‚ we first estimated the total number of patients that would require RBC transfusions divided in three main groups: Elective and emergency surgeries: The current market is of 7.9 million units‚ but there is also an unserved market of borderline transfusions that would require an additional 1.5 million units (1 million surgeries with requirements of 1-2 units / surgery)
Premium Blood Organ transplant Blood transfusion
HBR Case Study BY EDWARD E. LAWLER III COMMENTARY BY ANNA PRINGLE‚ F. LEIGH BRANHAM‚ JIM CORNELIUS‚ AND JEAN MARTIN Why Are We Losing All Our Good People? Sambian Partners has prided itself on being a great place to work‚ but now talented employees are leaving. What’s going on? MARY DONILLO‚ the head of human resources at Sambian Partners‚ motioned Tom Forsythe‚ Sambian’s assistant director of commercial design‚ to a comfortable chair in her office. It was late on a Thursday afternoon‚ and the
Premium Chief executive officer
Session 3 – Sep. 11 External Opportunities and Threats; Internal Strengths and Weaknesses Read: Day - Scanning the Periphery (HBR‚ Nov 05) (Reserves) Case Preparation: Netflix (Case Pack) 1. What distinctive organizational resources and core competencies has Netflix developed over the course of its existence? Which ones are most important to its survival? 2. Has Netflix developed a sustainable competitive advantage against its
Premium Renting Commerce Rental shop
Executive Summary Biopure Corporation was established in 1984 and is a privately owned pharmaceutical firm. They are trying to launch two new products: Hemopure (human market) and Oxyglobin (veterinary market). They are the only company aggressively engaged in the development of blood substitutes for the vet market. Biopure has invested $200M in the development of said blood substitutes. They currently don’t have any revenues with little to no debt and financing of $50M to support these operations
Premium Health care Net present value Medicine
Biopure Case Study Executive Summary * Biopure Corporation developed two new products to enter into the field of blood substitutes: Hemopure‚ directed to the human market and Oxyglobin‚ for the veterinary market. Through the end of 1997 no blood substitute had received approval for use anywhere in the world. * What distinguishes both products from other “hemoglobin-based” blood substitutes is the fact that they are “bovine-sourced” as opposed to “human-sourced”‚ i.e. they are derived from
Free Blood Blood transfusion